Mittal Shuchi, Bjørnevik Kjetil, Im Doo Soon, Flierl Adrian, Dong Xianjun, Locascio Joseph J, Abo Kristine M, Long Elizabeth, Jin Ming, Xu Bing, Xiang Yang K, Rochet Jean-Christophe, Engeland Anders, Rizzu Patrizia, Heutink Peter, Bartels Tim, Selkoe Dennis J, Caldarone Barbara J, Glicksman Marcie A, Khurana Vikram, Schüle Birgitt, Park David S, Riise Trond, Scherzer Clemens R
Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Science. 2017 Sep 1;357(6354):891-898. doi: 10.1126/science.aaf3934.
Copy number mutations implicate excess production of α-synuclein as a possibly causative factor in Parkinson's disease (PD). Using an unbiased screen targeting endogenous gene expression, we discovered that the β2-adrenoreceptor (β2AR) is a regulator of the α-synuclein gene (). β2AR ligands modulate transcription through histone 3 lysine 27 acetylation of its promoter and enhancers. Over 11 years of follow-up in 4 million Norwegians, the β2AR agonist salbutamol, a brain-penetrant asthma medication, was associated with reduced risk of developing PD (rate ratio, 0.66; 95% confidence interval, 0.58 to 0.76). Conversely, a β2AR antagonist correlated with increased risk. β2AR activation protected model mice and patient-derived cells. Thus, β2AR is linked to transcription of α-synuclein and risk of PD in a ligand-specific fashion and constitutes a potential target for therapies.
拷贝数突变表明α-突触核蛋白的过量产生可能是帕金森病(PD)的致病因素。通过针对内源性基因表达的无偏筛选,我们发现β2-肾上腺素能受体(β2AR)是α-突触核蛋白基因的调节因子。β2AR配体通过其启动子和增强子的组蛋白3赖氨酸27乙酰化来调节转录。在对400万挪威人进行的11年随访中,β2AR激动剂沙丁胺醇(一种可穿透大脑的哮喘药物)与患PD风险降低相关(率比为0.66;95%置信区间为0.58至0.76)。相反,β2AR拮抗剂与风险增加相关。β2AR激活对模型小鼠和患者来源的细胞具有保护作用。因此,β2AR以配体特异性方式与α-突触核蛋白的转录及PD风险相关联,并构成治疗的潜在靶点。